目的:探讨非小细胞肺癌(non-small cell lung cancer,NSCLC)组织中SLC22A18的表达与组织学类型、病理分级的关系,以及与相应癌组织对化疗药物敏感性的相关性。方法:应用免疫组化EnVinsion法,检测第四军医大学唐都医院胸外科2005-10-1-2006-06-30手术切除96例NSCLC组织中SLC22A18表达;MTT法检测相应96例癌组织对9种化疗药物的敏感性,分析其与SLC22A18表达的相关性。结果:SLC22A18主要定位于胞膜上和胞质中。在鳞癌、腺癌组织中阳性率分别为68.0%(34/50)和78.2%(36/46),差异有统计学意义,P=0.015。鳞癌Ⅱ、Ⅲ级组织阳性率分别为54.2%(13/24)和80.8%(21/26),差异有统计学意义,P=0.041。腺癌中分化、低分化阳性率分别为69.6%(16/23)和86.9%(20/23),差异有统计学意义,P=0.007。NSCLC组织SLC22A18的表达与其相应组织药物敏感性试验做两因素方差分析,其中环磷酰胺、5-FU、紫杉醇、长春瑞滨、多西他赛和卡铂的P值分别为0.002、<0.001、0.005、0.043、0.001和0.028。结论:SLC22A18在NSCLC组织中高表达,在腺癌中的表达率高于鳞癌,分化越差,表达越高;NSCLC组织中SLC22A18的表达对组织耐药性的产生发挥作用。 Objective: To investigate the relationship between the expression of SLC22A18 and the histological type and pathological grade in non-small cell lung cancer (NSCLC) and its relationship with chemosensitivity of corresponding cancer tissues. Methods: The immunohistochemical EnVionion method was used to detect the expression of SLC22A18 in 96 cases of NSCLC tissues from October 2005 to June 2006 in Department of Thoracic Surgery, Tangdu Hospital, Fourth Military Medical University. The corresponding 96 cases of cancerous tissues were detected by MTT assay The chemosensitivity of chemotherapeutic agents was analyzed and their correlation with SLC22A18 expression was analyzed. Results: SLC22A18 mainly located in the membrane and cytoplasm. The positive rates in squamous cell carcinoma and adenocarcinoma were 68.0% (34/50) and 78.2% (36/46), respectively, with statistical significance (P = 0.015). The positive rates of grade Ⅱ and grade Ⅲ in squamous cell carcinoma were 54.2% (13/24) and 80.8% (21/26), respectively, with statistical significance (P = 0.041). The positive rates of differentiation and poor differentiation in adenocarcinoma were 69.6% (16/23) and 86.9% (20/23) respectively, with a significant difference (P = 0.007). SLC22A18 expression in NSCLC tissue and its corresponding drug susceptibility testing to do two-way ANOVA, which cyclophosphamide, 5-FU, paclitaxel, vinorelbine, docetaxel and carboplatin, respectively, P = 0.002, <0.001, 0.005, 0.043, 0.001 and 0.028. CONCLUSIONS: SLC22A18 is highly expressed in NSCLC tissues and higher in adenocarcinoma than in squamous cell carcinoma. The higher the expression of SLC22A18 is, the higher the expression of SLC22A18 is. The expression of SLC22A18 plays a role in the development of tissue drug resistance.